Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Regression of Atherosclerosis

This systematic review and meta-analysis pooled data from randomized trials of ezetimibe added to statin therapy — including the landmark IMPROVE-IT trial — across 31,048 patients to assess cardiovascular outcomes and atherosclerosis regression effects.

Adding ezetimibe to statin therapy significantly reduced MI risk (RR 0.865, p<0.001) and stroke risk (RR 0.840, p=0.002) compared with statin monotherapy or control. All-cause mortality and cardiovascular mortality were not significantly different. In imaging sub-studies, ezetimibe plus statin produced greater atherosclerosis regression than statin alone, consistent with the additional LDL-C reduction achieved.

The finding is important because ezetimibe was for years viewed skeptically — its LDL-C lowering was known, but the question was whether further LDL-C reduction via a non-statin mechanism would translate to clinical benefit. The IMPROVE-IT trial answer was yes — though with a modest absolute benefit reflecting the population’s already-treated baseline risk. This meta-analysis confirmed and extended that finding.

The ezetimibe result also validated the LDL-C–lowering hypothesis independent of statins: different drug class, different mechanism, same directional benefit proportional to LDL-C reduction. This is the key evidence establishing that the statin benefits are mediated by LDL-C lowering, not by statin-specific pleiotropic effects.

We rate the evidence strong. A well-executed meta-analysis confirming incremental cardiovascular benefit when ezetimibe is added to statins — establishing ezetimibe as the first-line adjunct for patients not at LDL-C goal on statins alone.